US FDA’s Anti-Misinformation Campaigns Look Safer After Supreme Court Oral Arguments

FDA’s efforts to tackle misinformation may face fewer legal obstacles moving forward, following oral arguments at the Supreme Court on a case that could have broad ramifications for how the government communicates public health information.

outside of the US Supreme Court building
The Supreme Court heard oral arguments on 18 March in a case stemming from government actions on COVID-19 misinformation. • Source: Shutterstock (Erik Cox Photography)

The US Food and Drug Administration’s ability to communicate with social media companies like Facebook about inaccurate scientific and medical information is likely on safer grounds following oral arguments at the Supreme Court on 18 March.

The majority of the justices seemed unlikely to uphold a US Court of Appeals for the 5th Circuit ruling that...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet